• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SARS-CoV-2 病毒进入和复制由于 ACE2 下调而在囊性纤维化气道中受损。

SARS-CoV-2 viral entry and replication is impaired in Cystic Fibrosis airways due to ACE2 downregulation.

机构信息

Cystic Fibrosis Center of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

Section of Clinical Biochemistry, University of Verona, Verona, Italy.

出版信息

Nat Commun. 2023 Jan 10;14(1):132. doi: 10.1038/s41467-023-35862-0.

DOI:10.1038/s41467-023-35862-0
PMID:36627352
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9830623/
Abstract

As an inherited disorder characterized by severe pulmonary disease, cystic fibrosis could be considered a comorbidity for coronavirus disease 2019. Instead, current clinical evidence seems to be heading in the opposite direction. To clarify whether host factors expressed by the Cystic Fibrosis epithelia may influence coronavirus disease 2019 progression, here we describe the expression of SARS-CoV-2 receptors in primary airway epithelial cells. We show that angiotensin converting enzyme 2 (ACE2) expression and localization are regulated by Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) channel. Consistently, our results indicate that dysfunctional CFTR channels alter susceptibility to SARS-CoV-2 infection, resulting in reduced viral entry and replication in Cystic Fibrosis cells. Depending on the pattern of ACE2 expression, the SARS-CoV-2 spike (S) protein induced high levels of Interleukin 6 in healthy donor-derived primary airway epithelial cells, but a very weak response in primary Cystic Fibrosis cells. Collectively, these data support that Cystic Fibrosis condition may be at least partially protecting from SARS-CoV-2 infection.

摘要

作为一种以严重肺部疾病为特征的遗传性疾病,囊性纤维化可以被认为是 2019 年冠状病毒病的合并症。然而,目前的临床证据似乎指向相反的方向。为了阐明囊性纤维化上皮细胞表达的宿主因素是否可能影响 2019 年冠状病毒病的进展,我们在这里描述了 SARS-CoV-2 受体在原代气道上皮细胞中的表达。我们表明,血管紧张素转换酶 2(ACE2)的表达和定位受囊性纤维化跨膜电导调节因子(CFTR)通道调节。一致地,我们的结果表明,功能失调的 CFTR 通道改变了对 SARS-CoV-2 感染的易感性,导致囊性纤维化细胞中的病毒进入和复制减少。根据 ACE2 表达的模式,SARS-CoV-2 刺突(S)蛋白在健康供体来源的原代气道上皮细胞中诱导高水平的白细胞介素 6,但在原代囊性纤维化细胞中反应非常弱。总的来说,这些数据支持囊性纤维化的状况至少可能部分地保护免受 SARS-CoV-2 感染。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e07/9832122/cd2b0b3234e7/41467_2023_35862_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e07/9832122/5f205b3e6cb4/41467_2023_35862_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e07/9832122/c2c511df5f4c/41467_2023_35862_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e07/9832122/b9c54e2758be/41467_2023_35862_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e07/9832122/50faf5c18cb9/41467_2023_35862_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e07/9832122/66cae42ea83e/41467_2023_35862_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e07/9832122/6dfd9d5683ee/41467_2023_35862_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e07/9832122/cd2b0b3234e7/41467_2023_35862_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e07/9832122/5f205b3e6cb4/41467_2023_35862_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e07/9832122/c2c511df5f4c/41467_2023_35862_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e07/9832122/b9c54e2758be/41467_2023_35862_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e07/9832122/50faf5c18cb9/41467_2023_35862_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e07/9832122/66cae42ea83e/41467_2023_35862_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e07/9832122/6dfd9d5683ee/41467_2023_35862_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e07/9832122/cd2b0b3234e7/41467_2023_35862_Fig7_HTML.jpg

相似文献

1
SARS-CoV-2 viral entry and replication is impaired in Cystic Fibrosis airways due to ACE2 downregulation.SARS-CoV-2 病毒进入和复制由于 ACE2 下调而在囊性纤维化气道中受损。
Nat Commun. 2023 Jan 10;14(1):132. doi: 10.1038/s41467-023-35862-0.
2
TGF-β1 Inhibition of ACE2 Mediated by miRNA Uncovers Novel Mechanism of SARS-CoV-2 Pathogenesis.TGF-β1 通过 miRNA 抑制 ACE2 揭示了 SARS-CoV-2 发病机制的新机制。
J Innate Immun. 2023;15(1):629-646. doi: 10.1159/000533606. Epub 2023 Aug 14.
3
Epstein-Barr Virus Lytic Replication Induces ACE2 Expression and Enhances SARS-CoV-2 Pseudotyped Virus Entry in Epithelial Cells.疱疹病毒 4 型(EBV)裂解复制诱导 ACE2 表达并增强 SARS-CoV-2 假型病毒进入上皮细胞。
J Virol. 2021 Jun 10;95(13):e0019221. doi: 10.1128/JVI.00192-21.
4
Inflammation in the COVID-19 airway is due to inhibition of CFTR signaling by the SARS-CoV-2 spike protein.在 COVID-19 气道中的炎症是由于 SARS-CoV-2 刺突蛋白抑制 CFTR 信号通路引起的。
Sci Rep. 2024 Jul 23;14(1):16895. doi: 10.1038/s41598-024-66473-4.
5
Functional and genetic analysis of viral receptor ACE2 orthologs reveals a broad potential host range of SARS-CoV-2.病毒受体ACE2直系同源物的功能和遗传分析揭示了SARS-CoV-2广泛的潜在宿主范围。
Proc Natl Acad Sci U S A. 2021 Mar 23;118(12). doi: 10.1073/pnas.2025373118.
6
Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.血管紧张素转换酶 2(ACE2)在 COVID-19 所致急性呼吸窘迫综合征发病机制中的作用。
Front Immunol. 2021 Dec 22;12:732690. doi: 10.3389/fimmu.2021.732690. eCollection 2021.
7
Mechanisms by which the cystic fibrosis transmembrane conductance regulator may influence SARS-CoV-2 infection and COVID-19 disease severity.囊性纤维化跨膜电导调节因子可能影响 SARS-CoV-2 感染和 COVID-19 疾病严重程度的机制。
FASEB J. 2023 Nov;37(11):e23220. doi: 10.1096/fj.202300077R.
8
The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.TMPRSS2 抑制剂那法莫司他可降低 COVID-19 小鼠模型中的 SARS-CoV-2 肺部感染。
mBio. 2021 Aug 31;12(4):e0097021. doi: 10.1128/mBio.00970-21. Epub 2021 Aug 3.
9
Classical and alternative receptors for SARS-CoV-2 therapeutic strategy.经典和替代 SARS-CoV-2 治疗策略受体。
Rev Med Virol. 2021 Sep;31(5):1-9. doi: 10.1002/rmv.2207. Epub 2020 Dec 26.
10
Nonmuscle myosin heavy chain IIA facilitates SARS-CoV-2 infection in human pulmonary cells.非肌肉肌球蛋白重链 IIA 促进 SARS-CoV-2 感染人肺细胞。
Proc Natl Acad Sci U S A. 2021 Dec 14;118(50). doi: 10.1073/pnas.2111011118.

引用本文的文献

1
Diagnosis and Emerging Biomarkers of Cystic Fibrosis-Related Kidney Disease (CFKD).囊性纤维化相关肾病(CFKD)的诊断与新兴生物标志物
J Clin Med. 2025 Aug 7;14(15):5585. doi: 10.3390/jcm14155585.
2
Potential Resistance Mechanisms Exhibited by Cystic Fibrosis Patients Against SARS-CoV-2.囊性纤维化患者对SARS-CoV-2表现出的潜在抵抗机制。
Viruses. 2025 Jun 27;17(7):919. doi: 10.3390/v17070919.
3
Uncomplicated SARS-CoV-2 Infections with Preserved Lung Function in Pediatric Patients with Cystic Fibrosis: A Three-Year Single-Centre Experience.

本文引用的文献

1
CFTR Modulation Reduces SARS-CoV-2 Infection in Human Bronchial Epithelial Cells.CFTR 调节剂可降低人支气管上皮细胞中 SARS-CoV-2 的感染。
Cells. 2022 Apr 15;11(8):1347. doi: 10.3390/cells11081347.
2
Overview of CF lung pathophysiology.CF 肺生理学病理概述。
Curr Opin Pharmacol. 2022 Jun;64:102214. doi: 10.1016/j.coph.2022.102214. Epub 2022 Apr 19.
3
One year monitoring of SARS-CoV-2 prevalence in a German cohort of patients with cystic fibrosis.对德国囊性纤维化患者队列中 SARS-CoV-2 流行情况进行的为期一年的监测。
囊性纤维化患儿中肺功能正常的单纯性新型冠状病毒感染:一项为期三年的单中心经验
J Clin Med. 2025 Apr 25;14(9):2979. doi: 10.3390/jcm14092979.
4
Synthesis, molecular docking, and activity of a novel angiotensin-converting enzyme 2 inhibitor, LMS1007: a potential molecule in Covid-19 and cancer treatments.新型血管紧张素转换酶2抑制剂LMS1007的合成、分子对接及活性:一种在新冠病毒病和癌症治疗中具有潜力的分子
RSC Adv. 2025 May 8;15(19):15138-15154. doi: 10.1039/d5ra01134e. eCollection 2025 May 6.
5
Divergent responses to SARS-CoV-2 infection in bronchial epithelium with pre-existing respiratory diseases.患有既往呼吸系统疾病的支气管上皮细胞对SARS-CoV-2感染的不同反应。
iScience. 2025 Feb 12;28(3):111999. doi: 10.1016/j.isci.2025.111999. eCollection 2025 Mar 21.
6
Distinct Responses of Cystic Fibrosis Epithelial Cells to SARS-CoV-2 and Influenza A Virus.囊性纤维化上皮细胞对严重急性呼吸综合征冠状病毒2和甲型流感病毒的不同反应。
Am J Respir Cell Mol Biol. 2025 Mar;72(3):308-319. doi: 10.1165/rcmb.2024-0213OC.
7
CFTR Inhibitors Display Antiviral Activity against Herpes Simplex Virus.CFTR 抑制剂对单纯疱疹病毒显示抗病毒活性。
Viruses. 2024 Aug 16;16(8):1308. doi: 10.3390/v16081308.
8
Inflammation in the COVID-19 airway is due to inhibition of CFTR signaling by the SARS-CoV-2 spike protein.在 COVID-19 气道中的炎症是由于 SARS-CoV-2 刺突蛋白抑制 CFTR 信号通路引起的。
Sci Rep. 2024 Jul 23;14(1):16895. doi: 10.1038/s41598-024-66473-4.
9
Clinical Outcomes Following SARS-CoV-2 Infection in Pediatric Cystic Fibrosis Patients.儿童囊性纤维化患者感染新型冠状病毒 2 后的临床结局
Cureus. 2024 Jun 21;16(6):e62821. doi: 10.7759/cureus.62821. eCollection 2024 Jun.
10
Loss of CFTR Reverses Senescence Hallmarks in SARS-CoV-2 Infected Bronchial Epithelial Cells.CFTR 缺失可逆转 SARS-CoV-2 感染的支气管上皮细胞衰老特征。
Int J Mol Sci. 2024 Jun 4;25(11):6185. doi: 10.3390/ijms25116185.
BMC Pulm Med. 2022 Mar 24;22(1):101. doi: 10.1186/s12890-022-01900-8.
4
Factors for severe outcomes following SARS-CoV-2 infection in people with cystic fibrosis in Europe.欧洲囊性纤维化患者感染新型冠状病毒2后出现严重后果的因素。
ERJ Open Res. 2021 Dec 27;7(4). doi: 10.1183/23120541.00411-2021. eCollection 2021 Oct.
5
Clinical course and risk factors for severe COVID-19 among Italian patients with cystic fibrosis: a study within the Italian Cystic Fibrosis Society.意大利囊性纤维化协会研究:意大利囊性纤维化患者中严重 COVID-19 的临床病程和危险因素。
Infection. 2022 Jun;50(3):671-679. doi: 10.1007/s15010-021-01737-z. Epub 2021 Dec 7.
6
TLR3 and TLR7 RNA Sensor Activation during SARS-CoV-2 Infection.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染期间Toll样受体3(TLR3)和Toll样受体7(TLR7)RNA传感器的激活
Microorganisms. 2021 Aug 26;9(9):1820. doi: 10.3390/microorganisms9091820.
7
ACE2 interaction with cytoplasmic PDZ protein enhances SARS-CoV-2 invasion.血管紧张素转换酶2(ACE2)与细胞质PDZ蛋白的相互作用增强了新型冠状病毒2(SARS-CoV-2)的入侵。
iScience. 2021 Jul 23;24(7):102770. doi: 10.1016/j.isci.2021.102770. Epub 2021 Jun 24.
8
Chronic bacterial pulmonary infections in advanced cystic fibrosis differently affect the level of sputum neutrophil elastase, IL-8 and IL-6.慢性细菌性肺部感染在晚期囊性纤维化中对痰中性粒细胞弹性蛋白酶、IL-8 和 IL-6 的水平有不同的影响。
Clin Exp Immunol. 2021 Sep;205(3):391-405. doi: 10.1111/cei.13624. Epub 2021 Jun 16.
9
Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020.2020 年 2 月至 6 月期间欧洲囊性纤维化患者中 SARS-CoV-2 的发病率。
J Cyst Fibros. 2021 Jul;20(4):566-577. doi: 10.1016/j.jcf.2021.03.017. Epub 2021 Apr 18.
10
SARS-CoV-2 infection in cystic fibrosis: A multicentre prospective study with a control group, Italy, February-July 2020.囊性纤维化患者的新型冠状病毒2型感染:一项设有对照组的多中心前瞻性研究,意大利,2020年2月至7月
PLoS One. 2021 May 13;16(5):e0251527. doi: 10.1371/journal.pone.0251527. eCollection 2021.